System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 39624020 DOI: 10.1002/art.43069

Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.

Arthritis Rheumatol 77(5):536-546

Authors: Denis Poddubnyy, Bhumik Parikh, Dirk Elewaut, Victoria Navarro-Compán, Stefan Siebert, Michael Paley, Derek Coombs, Ivan Lagunes, Ana Biljan, Priscila Nakasato, Peter Wung, Ennio Lubrano

Affiliations

  • University of Toronto, Toronto, Ontario, Canada, and Charité-Universitätsmedizin, Berlin, Germany.
  • AbbVie, Inc, North Chicago, Illinois.
  • Ghent University Hospital and Ghent University, Ghent, Belgium.
  • Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
  • University of Glasgow, Glasgow, United Kingdom.
  • Washington University School of Medicine, St. Louis, Missouri.
  • University of Molise, Campobasso, Italy.

Abstract

OBJECTIVE

To assess the development of extramusculoskeletal manifestations (EMMs) among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with upadacitinib 15 mg.

METHODS

Data (cutoff: August 15, 2022) from five clinical trials in PsA (2), radiographic axSpA (r-axSpA; previously ankylosing spondylitis) (2), and nonradiographic axSpA (nr-axSpA) (1) were analyzed. Treatment-emergent adverse events of EMMs including uveitis, inflammatory bowel disease (IBD), and psoriasis were assessed in patients treated with placebo, upadacitinib 15 mg, or adalimumab (PsA only) and are reported as exposure-adjusted event rates (events per 100 patient-years [E/100 PY]).

RESULTS

Most patients (87.1%-99.3%) did not have a history of EMMs at baseline. In PsA, development of uveitis and IBD were low regardless of treatment or prior EMM history; rates were similar with upadacitinib 15 mg and adalimumab. In r-axSpA, development of uveitis was numerically lower (E/100 PY) in patients treated with upadacitinib 15 mg (2.8) versus placebo (7.5) and in patients with no history of uveitis (upadacitinib 15 mg 0.6; placebo 1.2) versus a history of uveitis (upadacitinib 15 mg 2.1; placebo 6.2); occurrence of IBD and psoriasis were low regardless of treatment or history. In nr-axSpA, development of uveitis was low regardless of history but was numerically lower in patients treated with upadacitinib 15 mg (0.9) versus placebo (2.1); occurrence of IBD and psoriasis were low or absent.

CONCLUSION

In patients with spondyloarthritis, development of EMMs was generally low with upadacitinib 15 mg. Uveitis was numerically lower in patients treated with upadacitinib 15 mg versus placebo, and particularly in r-axSpA. Regardless of treatment in r-axSpA, having a history of uveitis appeared to predispose patients for future uveitis events.

MeSH

Arthritis, Psoriatic, Arthritis, Rheumatic Diseases, Therapeutics, History, Psoriasis, Uveitis, Axial Spondyloarthritis